Skip to content
The Nexus
HEALTHJun 29 · 13:52 UTCSTAT NEWSMeghana Keshavan

STAT+: Talawar bets bispecific approach can shake up eczema market

Talawar is leveraging a bispecific approach to potentially disrupt the eczema market. The article also highlights a SPAC for a bispecific maker, Moderna's advancing mRNA ambitions, and Clive Meanwell's perspective on AI's role in biotech drug design.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Talawarorganizationbispecific approachtopicEczematopicSPACtopicModernaorganizationClive MeanwellpersonAItopicmRNAtopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting